Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Endo raises FY21 adjusted EPS view to $1.95-$2.30 from $1.80-$2.30 » 16:38
05/06/21
05/06
16:38
05/06/21
16:38
ENDP

Endo

$5.43 /

-0.14 (-2.51%)

FY21 consensus $2.11.…

FY21 consensus $2.11. Raises FY21 revenue view to $2.65B-$2.79B from $2.55B-$2.79B, consensus $2.7B.

ShowHide Related Items >><<
ENDP Endo
$5.43 /

-0.14 (-2.51%)

ENDP Endo
$5.43 /

-0.14 (-2.51%)

04/06/21 RBC Capital
Endo transferred with a Sector Perform at RBC Capital
03/08/21 Barclays
Endo price target raised to $7 from $6 at Barclays
03/04/21 Citi
Endo price target lowered to $10 from $11 at Citi
01/19/21 Citi
Endo price target raised to $9 from $7 at Citi
ENDP Endo
$5.43 /

-0.14 (-2.51%)

ENDP Endo
$5.43 /

-0.14 (-2.51%)

ENDP Endo
$5.43 /

-0.14 (-2.51%)

ENDP Endo
$5.43 /

-0.14 (-2.51%)

Earnings
Endo reports Q1 adjusted cont ops EPS 73c, consensus 48c » 16:35
05/06/21
05/06
16:35
05/06/21
16:35
ENDP

Endo

$5.43 /

-0.14 (-2.51%)

Reports Q1 revenue…

Reports Q1 revenue $717.92M, consensus $668.65M.

ShowHide Related Items >><<
ENDP Endo
$5.43 /

-0.14 (-2.51%)

ENDP Endo
$5.43 /

-0.14 (-2.51%)

04/06/21 RBC Capital
Endo transferred with a Sector Perform at RBC Capital
03/08/21 Barclays
Endo price target raised to $7 from $6 at Barclays
03/04/21 Citi
Endo price target lowered to $10 from $11 at Citi
01/19/21 Citi
Endo price target raised to $9 from $7 at Citi
ENDP Endo
$5.43 /

-0.14 (-2.51%)

ENDP Endo
$5.43 /

-0.14 (-2.51%)

ENDP Endo
$5.43 /

-0.14 (-2.51%)

ENDP Endo
$5.43 /

-0.14 (-2.51%)

Over a week ago
Hot Stocks
Endo names Mark Barberio Chairman of Board of Directors » 16:18
04/27/21
04/27
16:18
04/27/21
16:18
ENDP

Endo

$6.09 /

+0.04 (+0.66%)

Endo International…

Endo International announced that Mark Barberio, who currently serves as an independent member of Endo's Board of Directors, has been appointed Chairman of the Board effective at the company's 2021 Annual General Meeting. Mr. Barberio's appointment is part of Endo's ongoing Board succession process, which has also included adding two new Board members since the company's 2020 Annual General Meeting. In addition, Paul Campanelli, who has served as Chairman of the Board since 2019 and who served as President and CEO from 2016 to 2020, will retire from the Board upon the expiration of his current term at the company's 2021 Annual General Meeting. Finally, Roger Kimmel, who has been Senior Independent Director since 2019 and who served as Chairman of the Board from 2014 to 2019, will also retire from the Board upon the expiration of his current term.

ShowHide Related Items >><<
ENDP Endo
$6.09 /

+0.04 (+0.66%)

ENDP Endo
$6.09 /

+0.04 (+0.66%)

04/06/21 RBC Capital
Endo transferred with a Sector Perform at RBC Capital
03/08/21 Barclays
Endo price target raised to $7 from $6 at Barclays
03/04/21 Citi
Endo price target lowered to $10 from $11 at Citi
01/19/21 Citi
Endo price target raised to $9 from $7 at Citi
ENDP Endo
$6.09 /

+0.04 (+0.66%)

ENDP Endo
$6.09 /

+0.04 (+0.66%)

ENDP Endo
$6.09 /

+0.04 (+0.66%)

ENDP Endo
$6.09 /

+0.04 (+0.66%)

Periodicals
California lawyer accuses drugmakers of causing opioid addiction, WSJ reports » 06:25
04/20/21
04/20
06:25
04/20/21
06:25
JNJ

Johnson & Johnson

$162.98 /

+0.83 (+0.51%)

, TEVA

Teva

$10.29 /

-0.46 (-4.28%)

, ENDP

Endo

$5.88 /

-0.38 (-6.07%)

, ABBV

AbbVie

$108.66 /

+0.73 (+0.68%)

A lawyer for several…

A lawyer for several California communities has accused Johnson & Johnson (JNJ), Teva (TEVA), Endo (ENDP), and AbbVie (ABBV) of causing a large wave of opioid addiction due to their aggressive marketing for pain pills, Sara Randazzo of The Wall Street Journal reports. The month long California trial, expected to start in May, could spur drugmakers to finalize settlements, with three large distributors and J&J already having proposed to pay a collective $26B to settle the case. Reference Link

ShowHide Related Items >><<
TEVA Teva
$10.29 /

-0.46 (-4.28%)

JNJ Johnson & Johnson
$162.98 /

+0.83 (+0.51%)

ENDP Endo
$5.88 /

-0.38 (-6.07%)

ABBV AbbVie
$108.66 /

+0.73 (+0.68%)

JNJ Johnson & Johnson
$162.98 /

+0.83 (+0.51%)

04/19/21 Chardan
Chardan sees J&J moving forward with Emergent if observations are minor
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/13/21 Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
TEVA Teva
$10.29 /

-0.46 (-4.28%)

04/06/21 RBC Capital
Teva transferred with a Sector Perform at RBC Capital
01/26/21 Piper Sandler
Amarin in 'strong position' against Health Net, says Piper Sandler
12/21/20 Gabelli
Teva named 'Best Idea for 2021' at Gabelli
11/27/20 H.C. Wainwright
Corcept Therapeutics price target raised to $32 from $22 at H.C. Wainwright
ENDP Endo
$5.88 /

-0.38 (-6.07%)

04/06/21 RBC Capital
Endo transferred with a Sector Perform at RBC Capital
03/08/21 Barclays
Endo price target raised to $7 from $6 at Barclays
03/04/21 Citi
Endo price target lowered to $10 from $11 at Citi
01/19/21 Citi
Endo price target raised to $9 from $7 at Citi
ABBV AbbVie
$108.66 /

+0.73 (+0.68%)

04/06/21 RBC Capital
AbbVie transferred with an Outperform at RBC Capital
04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
04/01/21 Piper Sandler
Piper migraine survey bearish for Amgen, bullish for Biohaven
03/17/21 JPMorgan
AbbVie selloff on Rinvoq deal 'appears overdone,' says JPMorgan
TEVA Teva
$10.29 /

-0.46 (-4.28%)

JNJ Johnson & Johnson
$162.98 /

+0.83 (+0.51%)

ENDP Endo
$5.88 /

-0.38 (-6.07%)

ABBV AbbVie
$108.66 /

+0.73 (+0.68%)

TEVA Teva
$10.29 /

-0.46 (-4.28%)

JNJ Johnson & Johnson
$162.98 /

+0.83 (+0.51%)

ENDP Endo
$5.88 /

-0.38 (-6.07%)

ABBV AbbVie
$108.66 /

+0.73 (+0.68%)

TEVA Teva
$10.29 /

-0.46 (-4.28%)

JNJ Johnson & Johnson
$162.98 /

+0.83 (+0.51%)

ENDP Endo
$5.88 /

-0.38 (-6.07%)

ABBV AbbVie
$108.66 /

+0.73 (+0.68%)

TEVA Teva
$10.29 /

-0.46 (-4.28%)

JNJ Johnson & Johnson
$162.98 /

+0.83 (+0.51%)

ENDP Endo
$5.88 /

-0.38 (-6.07%)

ABBV AbbVie
$108.66 /

+0.73 (+0.68%)

Hot Stocks
Results in Endo's phase 3 study show meaningful improvement in severe cellulite » 16:19
04/13/21
04/13
16:19
04/13/21
16:19
ENDP

Endo

$6.11 /

-0.07 (-1.13%)

The company states:…

The company states: "Endo International announced that Phase 3 data evaluating Qwo, or collagenase clostridium histolyticum-aaes for the treatment of moderate to severe cellulite in the buttocks of adult women was published in Dermatologic Surgery, the official journal of the American Society for Dermatologic Surgery. In addition to Phase 3 studies, the publication also includes a supplemental video that demonstrates the injection techniques for QWO. The Phase 3 studies, conducted from February 2018 to September 2018, demonstrated that QWO provides a clinically meaningful improvement in the appearance of moderate to severe cellulite in the buttocks of adult women compared to placebo. QWO received FDA approval in July 2020 and is the first and only injectable treatment for moderate to severe cellulite in the buttocks of adult women."

ShowHide Related Items >><<
ENDP Endo
$6.11 /

-0.07 (-1.13%)

ENDP Endo
$6.11 /

-0.07 (-1.13%)

04/06/21 RBC Capital
Endo transferred with a Sector Perform at RBC Capital
03/08/21 Barclays
Endo price target raised to $7 from $6 at Barclays
03/04/21 Citi
Endo price target lowered to $10 from $11 at Citi
01/19/21 Citi
Endo price target raised to $9 from $7 at Citi
ENDP Endo
$6.11 /

-0.07 (-1.13%)

ENDP Endo
$6.11 /

-0.07 (-1.13%)

ENDP Endo
$6.11 /

-0.07 (-1.13%)

ENDP Endo
$6.11 /

-0.07 (-1.13%)

Over a month ago
Hot Stocks
Endo comments on default liability judgment in Tennessee State court case » 09:26
04/07/21
04/07
09:26
04/07/21
09:26
ENDP

Endo

$7.39 /

+0.205 (+2.85%)

Endo announced the entry…

Endo announced the entry of an order granting a default judgment on liability against its wholly-owned subsidiaries Endo Health Solutions and Endo Pharmaceuticals in Staubus, et al. v. Purdue Pharma, L.P., et al., which has been pending in the Circuit Court at Kingsport, Tennessee since 2017. The Staubus case involves allegations by three Tennessee District Attorneys General and an individual plaintiff that EHSI's and EPI's sale of prescription opioid medications violated Tennessee's Drug Dealer Liability Act. In December, the Tennessee Supreme Court unanimously ruled that Tennessee's District Attorneys General do not have standing to bring claims under the DDLA. On April 5, the Staubus court permitted several Tennessee counties to substitute into the case in place of the District Attorney General plaintiffs. On April 6, the Staubus court entered a default judgment against Endo on liability as a sanction for alleged discovery improprieties. The order does not address the issue of damages, which the Staubus court ordered to be tried at a future date. Endo has made efforts to address the Staubus court's concerns, including by hiring an additional law firm, producing additional documents and offering additional depositions at Endo's expense. Endo "strongly disagrees" with the Staubus court's orders and will seek review of the Staubus court's orders by the Tennessee appellate courts.

ShowHide Related Items >><<
ENDP Endo
$7.39 /

+0.205 (+2.85%)

ENDP Endo
$7.39 /

+0.205 (+2.85%)

04/06/21 RBC Capital
Endo transferred with a Sector Perform at RBC Capital
03/08/21 Barclays
Endo price target raised to $7 from $6 at Barclays
03/04/21 Citi
Endo price target lowered to $10 from $11 at Citi
01/19/21 Citi
Endo price target raised to $9 from $7 at Citi
ENDP Endo
$7.39 /

+0.205 (+2.85%)

ENDP Endo
$7.39 /

+0.205 (+2.85%)

ENDP Endo
$7.39 /

+0.205 (+2.85%)

ENDP Endo
$7.39 /

+0.205 (+2.85%)

Recommendations
Endo transferred with a Sector Perform at RBC Capital » 16:50
04/06/21
04/06
16:50
04/06/21
16:50
ENDP

Endo

$7.39 /

+0.205 (+2.85%)

RBC Capital transferred…

RBC Capital transferred coverage of Endo to analyst Daniel Busby, and kept a Sector Perform rating and $7 price target on the stock.

ShowHide Related Items >><<
ENDP Endo
$7.39 /

+0.205 (+2.85%)

ENDP Endo
$7.39 /

+0.205 (+2.85%)

03/08/21 Barclays
Endo price target raised to $7 from $6 at Barclays
03/04/21 Citi
Endo price target lowered to $10 from $11 at Citi
01/19/21 Citi
Endo price target raised to $9 from $7 at Citi
01/04/21 Piper Sandler
Endo price target raised to $12 from $6 at Piper Sandler
ENDP Endo
$7.39 /

+0.205 (+2.85%)

ENDP Endo
$7.39 /

+0.205 (+2.85%)

ENDP Endo
$7.39 /

+0.205 (+2.85%)

ENDP Endo
$7.39 /

+0.205 (+2.85%)

Recommendations
Endo price target raised to $7 from $6 at Barclays » 09:01
03/08/21
03/08
09:01
03/08/21
09:01
ENDP

Endo

$6.99 /

+0.11 (+1.60%)

Barclays analyst Balaji…

Barclays analyst Balaji Prasad raised the firm's price target on Endo to $7 from $6 and keeps an Equal Weight rating on the shares. After holding an expert panel with two dermatologists to discuss the cellulite treatment landscape and potential for Endo's Qwo, the analyst is positive on the upcoming launch. The experts noted optimal Qwo pricing was very important for uptake, as consumers were unlikely to spend thousands of dollars on cellulite treatment, Prasad tells investors in a research note.

ShowHide Related Items >><<
ENDP Endo
$6.99 /

+0.11 (+1.60%)

ENDP Endo
$6.99 /

+0.11 (+1.60%)

03/04/21 Citi
Endo price target lowered to $10 from $11 at Citi
01/19/21 Citi
Endo price target raised to $9 from $7 at Citi
01/04/21 Piper Sandler
Endo price target raised to $12 from $6 at Piper Sandler
11/23/20 Citi
Citi recommends pair trade of overweight Endo, underweight Teva
ENDP Endo
$6.99 /

+0.11 (+1.60%)

ENDP Endo
$6.99 /

+0.11 (+1.60%)

ENDP Endo
$6.99 /

+0.11 (+1.60%)

ENDP Endo
$6.99 /

+0.11 (+1.60%)

Recommendations
Endo price target lowered to $10 from $11 at Citi » 06:28
03/04/21
03/04
06:28
03/04/21
06:28
ENDP

Endo

$6.86 /

-0.385 (-5.31%)

Citi analyst Navann Ty…

Citi analyst Navann Ty lowered the firm's price target on Endo to $10 from $11 and keeps a Buy rating on the shares. The stock dropped significantly after releasing "strong" fiscal 2020 earnings, driven by a lower than expected 2021 outlook, Ty tells investors in a research note. The analyst sill has a positive view of Qwo and Biospecifics, potential for a lower than expected opioid settlement and Novavax upside.

ShowHide Related Items >><<
ENDP Endo
$6.86 /

-0.385 (-5.31%)

ENDP Endo
$6.86 /

-0.385 (-5.31%)

01/19/21 Citi
Endo price target raised to $9 from $7 at Citi
01/04/21 Piper Sandler
Endo price target raised to $12 from $6 at Piper Sandler
11/23/20 Citi
Citi recommends pair trade of overweight Endo, underweight Teva
10/20/20 H.C. Wainwright
BioSpecifics downgraded to Neutral from Buy at H.C. Wainwright
ENDP Endo
$6.86 /

-0.385 (-5.31%)

ENDP Endo
$6.86 /

-0.385 (-5.31%)

ENDP Endo
$6.86 /

-0.385 (-5.31%)

ENDP Endo
$6.86 /

-0.385 (-5.31%)

Conference/Events
JPMorgan to hold a virtual conference » 04:55
03/03/21
03/03
04:55
03/03/21
04:55
ASGN

ASGN

$92.20 /

-3.06 (-3.21%)

, EBS

Emergent BioSolutions

$99.23 /

-2.965 (-2.90%)

, CEQP

Crestwood Equity

$23.31 /

+0.26 (+1.13%)

, TTMI

TTM Technologies

$14.12 /

-0.18 (-1.26%)

, SM

SM Energy

$13.82 /

-0.445 (-3.12%)

, SVRGF

Seven Generations

$0.00 /

+ (+0.00%)

, TLGHY

Telenet

$0.00 /

+ (+0.00%)

, ENDP

Endo

$7.25 /

-0.255 (-3.40%)

, MD

Mednax

$25.08 /

+0.59 (+2.41%)

, BZH

Beazer Homes

$19.04 /

+1.2 (+6.73%)

, CENT

Central Garden & Pet

$47.27 /

-0.11 (-0.23%)

, IT

Gartner

$183.25 /

-0.85 (-0.46%)

Global High Yield &…

Global High Yield & Leveraged Finance Virtual Conference will be held on March 1-3.

ShowHide Related Items >><<
TTMI TTM Technologies
$14.12 /

-0.18 (-1.26%)

SVRGF Seven Generations
$0.00 /

+ (+0.00%)

SM SM Energy
$13.82 /

-0.445 (-3.12%)

MD Mednax
$25.08 /

+0.59 (+2.41%)

IT Gartner
$183.25 /

-0.85 (-0.46%)

ENDP Endo
$7.25 /

-0.255 (-3.40%)

EBS Emergent BioSolutions
$99.23 /

-2.965 (-2.90%)

CENT Central Garden & Pet
$47.27 /

-0.11 (-0.23%)

BZH Beazer Homes
$19.04 /

+1.2 (+6.73%)

ASGN ASGN
$92.20 /

-3.06 (-3.21%)

ASGN ASGN
$92.20 /

-3.06 (-3.21%)

02/11/21 Truist
ASGN price target raised to $108 from $80 at Truist
11/23/20 BMO Capital
ASGN price target raised to $93 from $88 at BMO Capital
07/31/20 Truist
ASGN price target raised to $80 from $72 at SunTrust
07/30/20 Credit Suisse
ASGN price target raised to $60 from $50 at Credit Suisse
EBS Emergent BioSolutions
$99.23 /

-2.965 (-2.90%)

02/24/21 Chardan
Chardan reverses last week's downgrade, upgrades Emergent to Buy
02/24/21 Chardan
Emergent BioSolutions upgraded to Buy from Neutral at Chardan
02/19/21
Fly Intel: Top five analyst downgrades
02/19/21 Chardan
Emergent BioSolutions downgraded to Neutral from Buy at Chardan
CEQP Crestwood Equity
$23.31 /

+0.26 (+1.13%)

02/26/21 Wells Fargo
Crestwood Equity upgraded at Wells Fargo on 'solid' 2021 outlook
02/26/21 Wells Fargo
Crestwood Equity upgraded to Equal Weight from Underweight at Wells Fargo
02/16/21 Truist
Crestwood Equity upgraded to Buy from Hold at Truist
02/16/21 Truist
Crestwood Equity upgraded to Buy from Hold at Truist
TTMI TTM Technologies
$14.12 /

-0.18 (-1.26%)

02/04/21 B. Riley
TTM Technologies price target raised to $19.25 from $17.75 at B. Riley Securities
01/15/21 Truist
TTM Technologies price target raised to $16 from $15 at Truist
09/29/20 Craig-Hallum
Craig-Hallum bullish on TTM Technologies, initiates with a Buy
09/29/20 Craig-Hallum
TTM Technologies initiated with a Buy at Craig-Hallum
SM SM Energy
$13.82 /

-0.445 (-3.12%)

02/22/21 RBC Capital
SM Energy price target raised to $18 from $12 at RBC Capital
02/03/21 JPMorgan
SM Energy upgraded to Neutral with $13 target at JPMorgan
02/03/21 JPMorgan
SM Energy upgraded to Neutral from Underweight at JPMorgan
01/14/21 Barclays
SM Energy downgraded to Underweight from Equal Weight at Barclays
SVRGF Seven Generations
$0.00 /

+ (+0.00%)

02/19/21 National Bank
Seven Generations price target raised to C$14 from C$10 at National Bank
02/12/21 National Bank
Seven Generations downgraded to Tender from Outperform at National Bank
02/12/21 BMO Capital
Seven Generations downgraded to Market Perform from Outperform at BMO Capital
02/12/21 Stifel
ARC Resources price target raised to C$12.25 from C$10.75 at Stifel
TLGHY Telenet
$0.00 /

+ (+0.00%)

12/08/20 JPMorgan
Telenet upgraded to Overweight from Neutral at JPMorgan
11/04/20 UBS
Telenet price target lowered to EUR 33 from EUR 41.50 at UBS
10/23/20 Barclays
Telenet price target raised to EUR 43 from EUR 40 at Barclays
10/15/20 BofA
Telenet upgraded to Buy from Underperform at BofA
ENDP Endo
$7.25 /

-0.255 (-3.40%)

01/19/21 Citi
Endo price target raised to $9 from $7 at Citi
01/04/21 Piper Sandler
Endo price target raised to $12 from $6 at Piper Sandler
11/23/20 Citi
Citi recommends pair trade of overweight Endo, underweight Teva
10/20/20 H.C. Wainwright
BioSpecifics downgraded to Neutral from Buy at H.C. Wainwright
MD Mednax
$25.08 /

+0.59 (+2.41%)

02/19/21 Deutsche Bank
Mednax price target raised to $17.50 from $14 at Deutsche Bank
02/19/21 Citi
Mednax price target lowered to $22 from $24 at Citi
01/05/21 Truist
Mednax price target raised to $26 from $20 at Truist
10/19/20
Fly Intel: Top five analyst downgrades
BZH Beazer Homes
$19.04 /

+1.2 (+6.73%)

12/11/20 Sidoti
Beazer Homes initiated with a Buy at Sidoti
04/07/20 Wedbush
Beazer Homes price target lowered to $8 from $16 at Wedbush
CENT Central Garden & Pet
$47.27 /

-0.11 (-0.23%)

02/04/21 Truist
Central Garden & Pet price target raised to $45 from $40 at Truist
05/14/20 Truist
Scotts Miracle-Gro, Central Garden & Pet price targets raised at SunTrust
03/18/20 BofA
Central Garden & Pet upgraded to Buy from Neutral at BofA
03/18/20 BofA
Central Garden & Pet upgraded to Buy from Neutral at BofA
IT Gartner
$183.25 /

-0.85 (-0.46%)

02/10/21 Wells Fargo
Gartner price target raised to $187 from $145 at Wells Fargo
02/10/21 Barclays
Gartner price target raised to $185 from $134 at Barclays
01/13/21 KeyBanc
Windows upside could be limited with growth skewed to consumer, says KeyBanc
01/06/21 Morgan Stanley
Gartner upgraded to Overweight from Equal Weight at Morgan Stanley
TTMI TTM Technologies
$14.12 /

-0.18 (-1.26%)

SM SM Energy
$13.82 /

-0.445 (-3.12%)

MD Mednax
$25.08 /

+0.59 (+2.41%)

IT Gartner
$183.25 /

-0.85 (-0.46%)

ENDP Endo
$7.25 /

-0.255 (-3.40%)

EBS Emergent BioSolutions
$99.23 /

-2.965 (-2.90%)

CEQP Crestwood Equity
$23.31 /

+0.26 (+1.13%)

BZH Beazer Homes
$19.04 /

+1.2 (+6.73%)

ASGN ASGN
$92.20 /

-3.06 (-3.21%)

ENDP Endo
$7.25 /

-0.255 (-3.40%)

EBS Emergent BioSolutions
$99.23 /

-2.965 (-2.90%)

TTMI TTM Technologies
$14.12 /

-0.18 (-1.26%)

MD Mednax
$25.08 /

+0.59 (+2.41%)

ENDP Endo
$7.25 /

-0.255 (-3.40%)

BZH Beazer Homes
$19.04 /

+1.2 (+6.73%)

IT Gartner
$183.25 /

-0.85 (-0.46%)

ENDP Endo
$7.25 /

-0.255 (-3.40%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.